Clinical characteristics of male patients with breast cancer in the Latino population.

IF 3 3区 医学 Q2 ONCOLOGY Breast Cancer Research and Treatment Pub Date : 2024-10-29 DOI:10.1007/s10549-024-07525-1
Carlos González-Nuñez, Alejandro Mohar, Nancy Reynoso-Noverón, Rosa María Alvarez-Gómez, Yanin Chavarri-Guerra, Sergio Aguilar-Villanueva, Raúl Guzmán-Trigueros, Areli Velázquez-Martínez, Talía Wegman-Ostrosky, Fanny Porras-Reyes, Alexandra Garcilazo, Claudia Arce, Juan Enrique Bargallo-Rocha, Paula Cabrera-Galeana
{"title":"Clinical characteristics of male patients with breast cancer in the Latino population.","authors":"Carlos González-Nuñez, Alejandro Mohar, Nancy Reynoso-Noverón, Rosa María Alvarez-Gómez, Yanin Chavarri-Guerra, Sergio Aguilar-Villanueva, Raúl Guzmán-Trigueros, Areli Velázquez-Martínez, Talía Wegman-Ostrosky, Fanny Porras-Reyes, Alexandra Garcilazo, Claudia Arce, Juan Enrique Bargallo-Rocha, Paula Cabrera-Galeana","doi":"10.1007/s10549-024-07525-1","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>Breast cancer is the most prevalent cancer type in Mexico, with male breast cancer accounting for only 1% of all breast cancer cases. A limited number of studies have described the clinical-pathological profiles of males with breast cancer in low- and middle-income countries. This study presents an analysis of patients with breast cancer seen at three different institutions in México.</p><p><strong>Methods: </strong>A retrospective review of the medical records was performed to analyze the clinical and pathological characteristics of 49 men diagnosed with breast cancer and their overall survival.</p><p><strong>Results: </strong>The mean age at diagnosis was 64.65 years. A significant proportion of patients presented at diagnosis with stage IV disease (n = 11, 22.45%), had triple-negative subtype (n = 6, 12.24%), and nuclear grade III (n = 20, 40.8%). Primary endocrine resistance was observed in 10 patients (31.25%). Genetic analysis was performed on 24 patients (48.9%), revealing a germline BRCA pathogenic variant in 8.33%.</p><p><strong>Conclusion: </strong>Our findings described the clinical and pathological profile of breast cancer in a male cohort in Mexico, with a significantly high proportion of advanced disease, triple-negative subtype, nuclear grade III, and endocrine resistance. Further comprehensive studies, including research into somatic mutations, are needed.</p>","PeriodicalId":9133,"journal":{"name":"Breast Cancer Research and Treatment","volume":" ","pages":""},"PeriodicalIF":3.0000,"publicationDate":"2024-10-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Breast Cancer Research and Treatment","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s10549-024-07525-1","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Purpose: Breast cancer is the most prevalent cancer type in Mexico, with male breast cancer accounting for only 1% of all breast cancer cases. A limited number of studies have described the clinical-pathological profiles of males with breast cancer in low- and middle-income countries. This study presents an analysis of patients with breast cancer seen at three different institutions in México.

Methods: A retrospective review of the medical records was performed to analyze the clinical and pathological characteristics of 49 men diagnosed with breast cancer and their overall survival.

Results: The mean age at diagnosis was 64.65 years. A significant proportion of patients presented at diagnosis with stage IV disease (n = 11, 22.45%), had triple-negative subtype (n = 6, 12.24%), and nuclear grade III (n = 20, 40.8%). Primary endocrine resistance was observed in 10 patients (31.25%). Genetic analysis was performed on 24 patients (48.9%), revealing a germline BRCA pathogenic variant in 8.33%.

Conclusion: Our findings described the clinical and pathological profile of breast cancer in a male cohort in Mexico, with a significantly high proportion of advanced disease, triple-negative subtype, nuclear grade III, and endocrine resistance. Further comprehensive studies, including research into somatic mutations, are needed.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
拉丁裔男性乳腺癌患者的临床特征。
目的:乳腺癌是墨西哥发病率最高的癌症类型,而男性乳腺癌仅占所有乳腺癌病例的 1%。在低收入和中等收入国家,描述男性乳腺癌患者临床病理特征的研究数量有限。本研究对在墨西哥三家不同机构就诊的乳腺癌患者进行了分析:方法:对医疗记录进行回顾性审查,分析 49 名确诊为乳腺癌的男性患者的临床和病理特征及其总生存率:结果:确诊时的平均年龄为 64.65 岁。结果:确诊时的平均年龄为 64.65 岁,相当一部分患者在确诊时处于 IV 期(11 人,占 22.45%),三阴性亚型(6 人,占 12.24%),核分级为 III 级(20 人,占 40.8%)。10名患者(31.25%)出现原发性内分泌抵抗。对24名患者(48.9%)进行了基因分析,发现8.33%的患者存在种系BRCA致病变异:我们的研究结果描述了墨西哥男性群体中乳腺癌的临床和病理特征,其中晚期疾病、三阴性亚型、核分级 III 级和内分泌抵抗的比例明显较高。需要进一步开展全面研究,包括对体细胞突变的研究。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
6.80
自引率
2.60%
发文量
342
审稿时长
1 months
期刊介绍: Breast Cancer Research and Treatment provides the surgeon, radiotherapist, medical oncologist, endocrinologist, epidemiologist, immunologist or cell biologist investigating problems in breast cancer a single forum for communication. The journal creates a "market place" for breast cancer topics which cuts across all the usual lines of disciplines, providing a site for presenting pertinent investigations, and for discussing critical questions relevant to the entire field. It seeks to develop a new focus and new perspectives for all those concerned with breast cancer.
期刊最新文献
Correction: FBLN2 is associated with basal cell markers Krt14 and ITGB1 in mouse mammary epithelial cells and has a preferential expression in molecular subtypes of human breast cancer. A randomised trial comparing 6-monthly adjuvant zoledronate with a single one-time dose in patients with early breast cancer. Alterations in the expression of homologous recombination repair (HRR) genes in breast cancer tissues considering germline BRCA1/2 mutation status. Efficacy of antiobesity medications among breast cancer survivors taking aromatase inhibitors. Cost containment analysis of superparamagnetic iron oxide (SPIO) injection in patients with ductal carcinoma in situ.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1